Please check your internet connection and try again.
# Linagliptin
## Overview
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone concentrations, stimulating glucose-dependent insulin release and decreasing glucagon levels. It is unique among DPP-4 inhibitors for its primary biliary excretion and lack of significant renal clearance.
## Primary Indications
Type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control.
## Adult Dosing
* **Standard Dose:** 5 mg orally once daily.
* **Maximum Dose:** 5 mg daily.
## Pediatric Dosing
Safety and efficacy have not been established in patients younger than 18 years. Use is generally not recommended in the pediatric population.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment required.
* **Hepatic Impairment:** No dose adjustment required.
* **Geriatric:** No dose adjustment required based on age.
## Contraindications
* Hypersensitivity to linagliptin (anaphylaxis, angioedema, exfoliative skin conditions).
* History of pancreatitis (use caution/avoid).
## Adverse Effects
* **Common:** Nasopharyngitis, hypoglycemia (when used with secretagogues or insulin), hyperuricemia.
* **Serious:** Acute pancreatitis (rare), bullous pemphigoid, severe arthralgia (post-marketing reports), hypersensitivity reactions.
## Key Drug Interactions
* **Strong CYP3A4/P-gp Inducers (e.g., Rifampin):** May decrease linagliptin plasma concentrations. If coadministration is necessary, monitor glycemic control closely as efficacy may be reduced.
* **Insulin/Sulfonylureas:** Increased risk of hypoglycemia; dosage of the secretagogue may need reduction.
## Monitoring
* **Glycemic Control:** HbA1c (typically every 3 to 6 months), fasting plasma glucose.
* **Clinical:** Monitor for signs/symptoms of pancreatitis (persistent severe abdominal pain) and bullous pemphigoid (blistering/erosions).
## Clinical Pearls
* **Unique Elimination:** Linagliptin is the only DPP-4 inhibitor that does not require dose adjustment for renal impairment.
* **Administration:** May be taken with or without food.
* **Weight Neutral:** Generally considered weight-neutral.
* **Low Hypoglycemia Risk:** As a monotherapy, it has a low intrinsic risk of hypoglycemia because of its glucose-dependent mechanism.
***
**Educational Disclaimer:** This information is for educational purposes only. Always consult the most recent FDA-approved prescribing information or institutional clinical protocols before prescribing or administering medication. Consult a qualified healthcare professional for medical advice.
